Literature DB >> 25951887

Resolving quandaries: basaloid adenoid cystic carcinoma or breast cylindroma? The role of massively parallel sequencing.

Nicola Fusco1,2, Pierre-Emmanuel Colombo3, Luciano G Martelotto1, Maria R De Filippo1, Salvatore Piscuoglio1, Charlotte K Y Ng1, Raymond S Lim1, William Jacot3, Anne Vincent-Salomon4, Jorge S Reis-Filho1, Britta Weigelt1.   

Abstract

AIMS: The aims of this study were to perform a whole-exome sequencing analysis of a breast cylindroma and to investigate the role of molecular analyses in the differentiation between breast cylindroma, a benign tumour that displays MYB expression, and CYLD gene mutations, and its main differential diagnosis, the breast solid-basaloid adenoid cystic carcinoma, a malignant tumour that is characterized by the presence of the MYB-NFIB fusion gene and MYB overexpression. METHODS AND
RESULTS: A 66-year-old female underwent quadrantectomy after an irregular dense shadow was discovered in the right breast at the screening mammogram. Histologically, the tumour displayed features suggestive of a solid-basaloid variant of adenoid cystic carcinoma with a differential diagnosis of cylindroma. Fluorescence in situ hybridization, reverse transcription-polymerase chain reaction, immunohistochemistry and whole-exome sequencing revealed absence of the MYB-NFIB fusion gene, low levels of MYB protein expression and a clonal somatic CYLD splice site mutation associated with loss of heterozygosity of the wild-type allele.
CONCLUSIONS: The results of the histological, immunohistochemical and molecular analyses were consistent with a diagnosis of breast cylindroma, providing a proof-of-principle that the integration of histopathological and molecular approaches can help to differentiate between a low-malignant potential and a benign breast tumour of triple-negative phenotype.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  adenoid cystic carcinoma; breast cancer; cylindroma; fluorescence in-situ hybridization; massively parallel sequencing

Mesh:

Substances:

Year:  2015        PMID: 25951887      PMCID: PMC4637261          DOI: 10.1111/his.12735

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  35 in total

1.  Identification of the familial cylindromatosis tumour-suppressor gene.

Authors:  G R Bignell; W Warren; S Seal; M Takahashi; E Rapley; R Barfoot; H Green; C Brown; P J Biggs; S R Lakhani; C Jones; J Hansen; E Blair; B Hofmann; R Siebert; G Turner; D G Evans; C Schrander-Stumpel; F A Beemer; A van Den Ouweland; D Halley; B Delpech; M G Cleveland; I Leigh; J Leisti; S Rasmussen
Journal:  Nat Genet       Date:  2000-06       Impact factor: 38.330

2.  Expression of c-kit in adenoid cystic carcinoma of the breast.

Authors:  Giovanna M Crisi; Sharon A Marconi; Grace Makari-Judson; Robert A Goulart
Journal:  Am J Clin Pathol       Date:  2005-11       Impact factor: 2.493

3.  Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV.

Authors:  Jarupon Fah Sathirapongsasuti; Hane Lee; Basil A J Horst; Georg Brunner; Alistair J Cochran; Scott Binder; John Quackenbush; Stanley F Nelson
Journal:  Bioinformatics       Date:  2011-08-09       Impact factor: 6.937

4.  Solid variant of mammary adenoid cystic carcinoma with basaloid features: a study of nine cases.

Authors:  Sandra J Shin; Paul Peter Rosen
Journal:  Am J Surg Pathol       Date:  2002-04       Impact factor: 6.394

Review 5.  Adenoid cystic carcinomas of the breast and salivary glands (or 'The strange case of Dr Jekyll and Mr Hyde' of exocrine gland carcinomas).

Authors:  Caterina Marchiò; Britta Weigelt; Jorge S Reis-Filho
Journal:  J Clin Pathol       Date:  2010-03       Impact factor: 3.411

6.  Fine needle aspiration cytology of breast cylindroma in a woman with familial cylindromatosis: a case report.

Authors:  Nancy Wang; Rosemary Leeming; Fadi W Abdul-Karim
Journal:  Acta Cytol       Date:  2004 Nov-Dec       Impact factor: 2.319

Review 7.  Cylindromatosis and the CYLD gene: new lessons on the molecular principles of epithelial growth control.

Authors:  Ramin Massoumi; Ralf Paus
Journal:  Bioessays       Date:  2007-12       Impact factor: 4.345

8.  PLAG1 and CYLD do not play a role in the tumorigenesis of adenoid cystic carcinoma.

Authors:  Tsutomu Daa; Itaru Nakamura; Naomi Yada; Shigeki Arakane; Haruto Nishida; Kenji Kashima; Masashi Suzuki; Shigeo Yokoyama
Journal:  Mol Med Rep       Date:  2013-02-06       Impact factor: 2.952

9.  Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands.

Authors:  Ilan Weinreb; Salvatore Piscuoglio; Luciano G Martelotto; Daryl Waggott; Charlotte K Y Ng; Bayardo Perez-Ordonez; Nicholas J Harding; Javier Alfaro; Kenneth C Chu; Agnes Viale; Nicola Fusco; Arnaud da Cruz Paula; Caterina Marchio; Rita A Sakr; Raymond Lim; Lester D R Thompson; Simion I Chiosea; Raja R Seethala; Alena Skalova; Edward B Stelow; Isabel Fonseca; Adel Assaad; Christine How; Jianxin Wang; Richard de Borja; Michelle Chan-Seng-Yue; Christopher J Howlett; Anthony C Nichols; Y Hannah Wen; Nora Katabi; Nicholas Buchner; Laura Mullen; Thomas Kislinger; Bradly G Wouters; Fei-Fei Liu; Larry Norton; John D McPherson; Brian P Rubin; Blaise A Clarke; Britta Weigelt; Paul C Boutros; Jorge S Reis-Filho
Journal:  Nat Genet       Date:  2014-09-21       Impact factor: 38.330

10.  Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data.

Authors:  Valentina Boeva; Tatiana Popova; Kevin Bleakley; Pierre Chiche; Julie Cappo; Gudrun Schleiermacher; Isabelle Janoueix-Lerosey; Olivier Delattre; Emmanuel Barillot
Journal:  Bioinformatics       Date:  2011-12-06       Impact factor: 6.937

View more
  10 in total

1.  Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers.

Authors:  Giulia Ercoli; Gianluca Lopez; Camilla Ciapponi; Chiara Corti; Luca Despini; Donatella Gambini; Letterio Runza; Concetta Blundo; Amedeo Sciarra; Nicola Fusco
Journal:  J Vis Exp       Date:  2017-12-05       Impact factor: 1.355

2.  Spatio-Temporal Genomic Heterogeneity, Phylogeny, and Metastatic Evolution in Salivary Adenoid Cystic Carcinoma.

Authors:  Bin Liu; Yoshitsugu Mitani; Xiayu Rao; Mark Zafereo; Jianjun Zhang; Jianhua Zhang; P Andrew Futreal; Guillermina Lozano; Adel K El-Naggar
Journal:  J Natl Cancer Inst       Date:  2017-10-01       Impact factor: 13.506

3.  Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer.

Authors:  Nicola Fusco; Felipe C Geyer; Maria R De Filippo; Luciano G Martelotto; Charlotte K Y Ng; Salvatore Piscuoglio; Elena Guerini-Rocco; Anne M Schultheis; Laetitia Fuhrmann; Lu Wang; Achim A Jungbluth; Kathleen A Burke; Raymond S Lim; Anne Vincent-Salomon; Masamichi Bamba; Suzuko Moritani; Sunil S Badve; Shu Ichihara; Ian O Ellis; Jorge S Reis-Filho; Britta Weigelt
Journal:  Mod Pathol       Date:  2016-08-05       Impact factor: 7.842

4.  Similar outcomes between adenoid cystic carcinoma of the breast and invasive ductal carcinoma: a population-based study from the SEER 18 database.

Authors:  Qing-Xia Chen; Jun-Jing Li; Xiao-Xiao Wang; Pei-Yang Lin; Jie Zhang; Chuan-Gui Song; Zhi-Ming Shao
Journal:  Oncotarget       Date:  2017-01-24

5.  Cutaneous Adnexal Cylindroma of Breast: Epithelial Immunoreactivities for GATA-3, Mammaglobin, and E-Cadherin Do Not Equate to a Mammary Ductal Neoplasm.

Authors:  A Halima; A M Pannunzio; E M Erstine; J S Ko; W F Bergfeld; R M Malaya; M B Frankel; B C Calhoun; C D Sturgis
Journal:  Case Rep Pathol       Date:  2018-02-13

6.  Molecular Insights into the Classification of Luminal Breast Cancers: The Genomic Heterogeneity of Progesterone-Negative Tumors.

Authors:  Gianluca Lopez; Jole Costanza; Matteo Colleoni; Laura Fontana; Stefano Ferrero; Monica Miozzo; Nicola Fusco
Journal:  Int J Mol Sci       Date:  2019-01-25       Impact factor: 5.923

7.  Mismatch Repair Protein Loss as a Prognostic and Predictive Biomarker in Breast Cancers Regardless of Microsatellite Instability.

Authors:  Nicola Fusco; Gianluca Lopez; Chiara Corti; Chiara Pesenti; Patrizia Colapietro; Giulia Ercoli; Gabriella Gaudioso; Alice Faversani; Donatella Gambini; Anna Michelotti; Luca Despini; Concetta Blundo; Valentina Vaira; Monica Miozzo; Stefano Ferrero; Silvano Bosari
Journal:  JNCI Cancer Spectr       Date:  2018-12-13

8.  Genomic landscape of adenoid cystic carcinoma of the breast.

Authors:  Luciano G Martelotto; Maria R De Filippo; Charlotte K Y Ng; Rachael Natrajan; Laetitia Fuhrmann; Joanna Cyrta; Salvatore Piscuoglio; Huei-Chi Wen; Raymond S Lim; Ronglai Shen; Anne M Schultheis; Y Hannah Wen; Marcia Edelweiss; Odette Mariani; Göran Stenman; Timothy A Chan; Pierre-Emmanuel Colombo; Larry Norton; Anne Vincent-Salomon; Jorge S Reis-Filho; Britta Weigelt
Journal:  J Pathol       Date:  2015-07-14       Impact factor: 7.996

9.  The Contrasting Role of p16Ink4A Patterns of Expression in Neuroendocrine and Non-Neuroendocrine Lung Tumors: A Comprehensive Analysis with Clinicopathologic and Molecular Correlations.

Authors:  Nicola Fusco; Elena Guerini-Rocco; Alessandro Del Gobbo; Renato Franco; Federica Zito-Marino; Valentina Vaira; Gaetano Bulfamante; Giulia Ercoli; Mario Nosotti; Alessandro Palleschi; Silvano Bosari; Stefano Ferrero
Journal:  PLoS One       Date:  2015-12-16       Impact factor: 3.240

10.  Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary.

Authors:  Sarah H Kim; Arnaud Da Cruz Paula; Thais Basili; Higinio Dopeso; Rui Bi; Fresia Pareja; Edaise M da Silva; Rodrigo Gularte-Mérida; Zhen Sun; Sho Fujisawa; Caitlin G Smith; Lorenzo Ferrando; Ana Paula Martins Sebastião; Yonina Bykov; Anqi Li; Catarina Silveira; Charles W Ashley; Anthe Stylianou; Pier Selenica; Wesley R Samore; Achim A Jungbluth; Dmitriy Zamarin; Nadeem R Abu-Rustum; Kristian Helin; Robert A Soslow; Jorge S Reis-Filho; Esther Oliva; Britta Weigelt
Journal:  Nat Commun       Date:  2020-01-02       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.